
Lorazepam, sold under the brand name Ativan, is a benzodiazepine prescribed for anxiety. The United States Food and Drug Administration (FDA) label for Ativan indicates it for anxiety disorders or the short-term relief of anxiety symptoms, and it states that effectiveness beyond four months has not been systematically assessed. Many patients have taken it every day for years.
Like every benzodiazepine, lorazepam works by amplifying gamma-aminobutyric acid (GABA), the brain’s main calming signal. The Ashton Manual’s first chapter, on what benzodiazepines do in the body, describes how the nervous system adjusts over weeks and months, so the same dose does less over time. Past that point, a tablet that once treated anxiety is mostly holding off the withdrawal that would arrive without it.
That is physical dependence, and it does not require misuse. In its 2020 boxed-warning update for the whole benzodiazepine class, the FDA stated that physical dependence can occur when these drugs are taken steadily for several days to weeks, even as prescribed. So, how does a person come off of a medication the nervous system has come to expect?
A patient who has taken lorazepam 1 mg twice a day for six years has done nothing wrong. Physical dependence is not addiction. It is a predictable change in the nervous system caused by the medication, and it is treated by reversing that change slowly, not by a program built for compulsive drug use.
Unfortunately, the search for help often begins with the phrase “Ativan detox,” and it lands on addiction treatment facilities where a short stay and a fast taper are the opposite of what a lorazepam-dependent nervous system needs. Safe discontinuation is a gradual, medically supervised taper over months, sometimes longer, with the patient setting the pace. Cold turkey teaches no lesson. It only does harm.
Fortunately, the slow taper of lorazepam is well described, and the reason for its shape starts with the drug’s half-life.
Lorazepam is short acting and potent. Table 1 in the first chapter of the Ashton Manual lists its half-life at 10 to 20 hours, and the Ativan label puts the mean at about 12. The same table shows that 1 mg of lorazepam is roughly equal to 10 mg of diazepam (Valium).
A short half-life matters for a drug taken two or three times a day. Before the next dose is due, much of the last one is gone, and a dependent nervous system feels the gap as rising tension or a wave of dread that eases within an hour of the next tablet. This is interdose withdrawal, and it is easily mistaken for the original anxiety getting worse, which is how doses climb over the years.
It is also why stopping abruptly is dangerous. Rebound anxiety, insomnia, tremor, and, in some people, seizures can follow a sudden stop or a fast reduction, and the Ativan label warns that these withdrawal reactions can be life-threatening. A seizure is a medical emergency. Call 911 for a seizure or any other medical emergency, and call or text 988, the Suicide and Crisis Lifeline, if withdrawal brings thoughts of suicide.
Professor C. Heather Ashton wrote the Ashton Manual, and its Chapter II explains that with short-acting benzodiazepines such as lorazepam it is not possible to achieve a smooth decline in blood and tissue levels, and it advises switching to a long-acting benzodiazepine such as diazepam. Schedules 3 and 8 in the Manual are written for lorazepam, 6 mg and 3 mg daily, both with diazepam substitution.
The shape of a crossover taper is simple even where the arithmetic is not. One dose of the day at a time, part of the lorazepam is replaced by its equivalent in diazepam, each stage held for a week or two, until the whole daily amount is diazepam. Then the diazepam is lowered by a small amount, held, and lowered again, until it reaches zero many months later.
Think of keeping a bathtub at one level. Lorazepam is a bucket poured in twice a day, so the water rises and falls all day long, while diazepam is a tap left running slowly, so the level barely moves and the taper can turn it down a fraction at a time.
Professor Ashton’s own note on the schedules matters most: they have worked on real people, and they may need to be adapted to the person. The Manual is plain that the patient must be in control and proceed at a comfortable pace. The reasoning is laid out further in why the Ashton Manual recommends switching to diazepam before a benzo taper.
The crossover taper helps patients who feel the daily swing of a short-acting drug, and Dr. Leeds uses it when it fits. Yet, some patients do better staying on lorazepam and reducing it directly, because diazepam makes them drowsy or they would rather not add a second drug. For them, Dr. Leeds uses hyperbolic dose reductions, the approach described in the Maudsley Deprescribing Guidelines: each cut is a proportion of the current dose rather than a fixed amount, so the steps shrink as the dose falls.
Ativan tablets come in 0.5, 1, and 2 mg, and even half of the smallest is far too large a step near the end of a taper. So, Dr. Leeds often prescribes a liquid, either the lorazepam oral concentrate or a compounded oral liquid, which allows reductions of a fraction of a milligram.
Which route is right depends on the person, the dose, and what else is on board. Dr. Leeds also helps patients taper other psychiatric medications. The route is decided with the patient and revised as the taper goes.
There is no fixed timeline. Months is typical, and a year or more is not unusual after many years of daily use. The dose comes down by a small amount, holds until the nervous system has settled, then comes down again, and if a step does not settle, the hold is longer or the next step smaller. A hold is part of the taper, not a failure of it.
The pace is a negotiation between equals. If the taper is too fast, the doctor must slow it down, and if it is going well, patient and doctor may agree to go a little faster, as tolerated. Symptoms come in windows and waves, and a wave is not a sign that the taper has gone wrong.
The fear most patients bring is that the symptoms will never end. Not everyone’s symptoms stop when the drug does. Protracted withdrawal, in which symptoms continue for months after the last dose, is not rare, and the term benzodiazepine-induced neurological dysfunction (BIND) describes the wider condition: anxiety, insomnia, sensitivity to light and sound, cognitive difficulty, and nerve pain that can persist for months and sometimes years. The Ativan label itself describes a protracted withdrawal syndrome with symptoms lasting from weeks to more than 12 months.
An honest article does not call that temporary. It does get better with time as the nervous system heals, though slowly and unevenly, and there is usually nothing that moves it along faster. Fast tapers and abrupt stops raise the risk, and repeated stops and restarts sensitize the nervous system further, a pattern known as kindling.
Because lorazepam is prescribed for anxiety, every anxious morning during a taper looks like proof that the medication is still needed. Usually it is not. Withdrawal anxiety is the drug’s own calming effect running in reverse, and it settles as each step settles, which is one more reason the steps are small.
The Ativan label itself asks the prescribing physician to reassess periodically whether the drug is still useful for that patient, and it notes that the anxiety or tension of everyday stress usually does not call for an anxiolytic at all. A slow taper is the only way to find out how much of the anxiety was the drug and how much was the person. That question is answered near the end of the taper, not at the start, and it is one the patient and Dr. Leeds keep asking together.
Yes. Ativan is the brand name and lorazepam is the generic name for the same benzodiazepine. The same dependence, the same interdose withdrawal, and the same slow taper apply to both.
No. The crossover taper to diazepam is the Ashton Manual’s approach and suits many patients, but a direct taper of lorazepam with hyperbolic reductions and a liquid or compounded form is an alternative Dr. Leeds uses when it fits better.
Dr. Leeds is an osteopathic physician and deprescribing specialist in Fort Lauderdale, Florida, and he serves on the medical advisory board of the Benzodiazepine Information Coalition. His practice is concierge, not insurance, and provides medically supervised benzodiazepine tapering to patients in Florida only.
Care begins with informed consent in the true sense: risks first, the alternatives including waiting, an exit plan from day one, and the right to pause or decline at any point. There is no facility, no fixed taper timeline, and no meeting attendance, only one physician and one patient deciding each step together. Patients can read more about medically supervised benzodiazepine tapering and the Ashton Manual approach. Contact Dr. Leeds to ask about a lorazepam taper.
This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

Mark Leeds, D.O. is an osteopathic physician and deprescribing specialist in Fort Lauderdale, Florida. He helps patients come off benzodiazepines and sleeping pills with a slow, patient-directed taper guided by the Ashton Manual and the Maudsley Deprescribing Guidelines. Physical dependence is not addiction, and a careful taper is measured in months, not days.
Contact Us for expert guidance on safely tapering off benzodiazepines and reclaiming your life.





